{"entity":{"id":"nct05607004","kind":"trial","name":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","aka":[],"tldr":"A phase 2 trial of (Z)-endoxifen in HR-positive / HER2-negative breast cancer, run by Atossa Therapeutics, Inc., active and no longer recruiting.","summary":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer is a phase 2 interventional study registered as NCT05607004 by Atossa Therapeutics, Inc., with 87 participants enrolled, started 2023-02-14 and due to reach its primary completion in 2026-11. Interventions recorded: (Z)-endoxifen and goserelin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05607004","url":"https://clinicaltrials.gov/study/NCT05607004"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["atossa-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05607004","phase":"2","setting":"A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer","sponsor":"Atossa Therapeutics, Inc.","enrolled":87,"outcomes":[]},"route":"/trials/nct05607004/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"company":[{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/"}]}}